<DOC>
	<DOCNO>NCT02909751</DOCNO>
	<brief_summary>The purpose study investigate whether tocotrienol improve effect reduce side effect standard chemotherapy operation breast cancer .</brief_summary>
	<brief_title>Tocotrienol Combination With Neoadjuvant Chemotherapy Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<criteria>Women histologically verify breast cancer ( adenocarcinoma ) Age ≥ 18 year . Neoadjuvant treatment indicate accord departmental guideline PS 02 suit surgery . Normal heart function , LVEF ≥ 50 % MUGA/ECHO patient receive neoadjuvant trastuzumab Normal bone marrow function : Hemoglobin ≥ 6 mmol/l ; ANC ≥ 1.5x10^9/l ; Thrombocytes ≥ 100x10^9/l . Normal liver function : Bilirubin ≤ 1.5 x upper level normal , ALAT ≤ 2.5 x upper level normal , BASP ≤ 2.5 x upper level normal . Normal kidney function : Creatinine ≤ upper level normal . In case increase creatinine , measured/calculated GFR must ≥ 50 ml/min . Fertile woman must present negative pregnancy test use safe contraceptive 3 month treatment . Intrauterine device without hormone consider safe . Written orally inform consent Bilateral breast cancer suspect dissemination . Verified bilateral mammography , bone scintigraphy , chest abdomen CT , PETCT . Pregnant breastfeed woman Mental social condition prevent treatment followup Other simultaneous experimental treatment Immunosuppressive treatment ( prednisolone neoadjuvant chemotherapy ) Vitamin nutritional supplement ( multivitamin tablet calcium tablet vitamin D ) Active latent viral/bacterial infection Rheumatoid arthritis autoimmune disease Other malignant disease within past 5 year excl . nonmelanoma cancer skin carcinoma situ cervicis uterus . Previous treatment docetaxel , paclitaxel , epirubicin , cyclophosphamide , trastuzumab , pertuzumab tocotrienol Hypersensitivity active auxiliary substance</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>